Image 1 of 1
Semaglutide (commonly referred to as “Sema”) is a synthetic peptide engineered to engage key metabolic pathways involved in glucose regulation and energy homeostasis in laboratory research. Comprising 31 amino acids, Semaglutide incorporates strategic structural modifications—most notably the substitution of alanine with α-aminoisobutyric acid at position 8—to enhance enzymatic resistance to dipeptidyl peptidase-4 (DPP-4) degradation. Furthermore, its acylation with a hexadecandioic acid moiety enables strong albumin binding, extending its circulatory half-life and bioavailability.
In controlled research environments, Sema interacts with receptors central to metabolic regulation, influencing processes such as lipid metabolism, nutrient utilization, and energy expenditure in non-human test subjects. Findings from preclinical studies underscore its utility as a model compound for exploring mechanisms of metabolic signaling and energy balance.
Owing to its molecular stability and receptor selectivity, Semaglutide serves as a pivotal research tool for investigating complex physiological networks that govern glucose homeostasis and systemic metabolism in non-clinical experimental models.